Restless Legs Syndrome Is . . .

. . . Prevalent
According to the NINDS at NIH, Restless Legs Syndrome (RLS) is a common, underdiagnosed neurological condition that has components of both sleep and movement disorders. Patients with RLS have an irresistible urge to move their legs often associated with creeping, crawling, tingling, pulling and painful sensations in the legs when lying down or sitting for prolonged periods of time. It is estimated to affect 2-15% of the general population with a slightly higher incidence found in women. Occupational activities, social activities and family life are often affected as a result of this condition.

. . . a Mystery
RLS is a life-long condition for which there currently is no known cure. The cause of RLS is unknown. A family history of RLS is particularly common among patients whose symptoms appear before age 40. Secondary causes include iron deficiency, pregnancy, renal failure, diabetes and uremia.

. . . Treatable
While there are currently no approved medications to treat RLS in the US, dopamine agonists have been shown to be effective. Our development partner, Schwarz Pharma AG, has performed a pilot study that demonstrated Rotigotine, a transdermal skin patch with a novel dopamine agonist, produced a statistically significant improvement in symptoms. Schwarz Pharma is currently performing a European Phase IIb trial using rotigotine to treat RLS. For more information on this novel product currently in development by Schwarz Pharma AG , click here.

For a list of websites providing information on Restless Legs Syndrome, click here.

Reference:
Restless Legs Syndrome: Detection and Management in Primary Care; National Heart Lung and Blood Institute Working Group of Restless Legs Syndrome; NIH, Bethesda, MD; American Family Physician published by the American Academy of Family Physicians, July 1, 200. www.aafp.org/afp/20000701/108.html

back to top

---